Alzamend Neuro, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, announced its partnership with Massachusetts General Hospital…
ILiAD Biotechnologies, a biotech company developing the most advanced next-generation pertussis vaccine (BPZE1), announced today that Fierce Biotech has named the company to its Fierce 15 2024 list, recognizing ILiAD…
Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue Pharma L.P. (“Purdue”), has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to evaluate sunobinop…
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company focused on developing innovative biologic therapeutics, announced today that it has received approval from the European Medicines Agency (EMA) to commence a…
Bayer announced today that the FINEARTS-HF trial met its primary endpoint by achieving a statistically significant reduction in the composite of cardiovascular death and total (first and recurrent) heart failure…
The “U.S. Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report” for 2024-2030 has been added to ResearchAndMarkets.com’s portfolio. This report forecasts that the U.S. oligonucleotide synthesis market will reach…
bioAffinity Technologies today announced agreements with three accredited investors to exercise outstanding warrants, totaling 1,041,667 shares of common stock, for gross proceeds of approximately $1,302,083. In exchange, the investors will…
Amylyx Pharmaceuticals has received Orphan Drug Designation from the European Commission for AMX0035, its proprietary combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO) for treating Wolfram syndrome. This designation follows…
OS Therapies Announces Formation of Osteosarcoma Patient Advocacy Advisory Board OS Therapies, a biopharmaceutical company specializing in cancer immunotherapy and Antibody Drug Conjugates (ADCs), has announced the establishment of a…
Coya Therapeutics, a clinical-stage biotechnology firm specializing in biologics to enhance regulatory T cell (Treg) function, will present data from its phase 2, double-blind, placebo-controlled study of interleukin-2 (IL-2) for…
Agilent has announced that it has received FDA approval for the MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for…
Puma Biotechnology, a biopharmaceutical company, has released its financial results for the second quarter ending June 30, 2024. Comparisons are made between Q2 2024 and Q2 2023, unless specified otherwise.…